Santaris, GSK to Develop, Sell LNA-Based Antiviral Drugs; Santaris Could Gain $700M | GenomeWeb
Santaris Pharma and GlaxoSmithKline said this week that they will collaborate on the discovery, development, and commercialization of antiviral drugs based on Santaris’ locked nucleic acid technology.
 
Separately this week, Santaris said it has closed a €20.4 million ($30 million) Series C round of financing, which it said would enable it to remain solvent through the end of 2009.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.